 Amy Donahue
Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychotic Disorders | 1 | 2021 | 199 | 0.550 |
Why?
| | Telemedicine | 3 | 2022 | 978 | 0.510 |
Why?
| | Genomics | 2 | 2020 | 839 | 0.190 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2020 | 39 | 0.150 |
Why?
| | Biological Assay | 1 | 2020 | 134 | 0.150 |
Why?
| | Mental Health Services | 1 | 2022 | 478 | 0.130 |
Why?
| | Psychiatry | 1 | 2020 | 197 | 0.120 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 303 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2016 | 539 | 0.120 |
Why?
| | DNA Fingerprinting | 1 | 2016 | 28 | 0.120 |
Why?
| | Heterografts | 1 | 2016 | 143 | 0.110 |
Why?
| | Leukemia | 1 | 2016 | 247 | 0.100 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 169 | 0.100 |
Why?
| | Sequence Analysis, DNA | 2 | 2013 | 780 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2016 | 1794 | 0.090 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2013 | 261 | 0.080 |
Why?
| | Enhancer Elements, Genetic | 1 | 2011 | 191 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 3 | 2013 | 2458 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 499 | 0.070 |
Why?
| | Carrier Proteins | 1 | 2011 | 731 | 0.060 |
Why?
| | Pancreatic Neoplasms | 1 | 2013 | 947 | 0.050 |
Why?
| | Neoplasms | 1 | 2020 | 2946 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 928 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2223 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 414 | 0.050 |
Why?
| | Housing | 1 | 2022 | 142 | 0.040 |
Why?
| | Humans | 9 | 2022 | 147293 | 0.040 |
Why?
| | Limit of Detection | 1 | 2020 | 92 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 108 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2013 | 2679 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 2017 | 0.040 |
Why?
| | Perinatal Care | 1 | 2020 | 61 | 0.040 |
Why?
| | Exons | 1 | 2020 | 365 | 0.040 |
Why?
| | Mutation | 2 | 2020 | 4130 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 638 | 0.030 |
Why?
| | Blood Cells | 1 | 2016 | 38 | 0.030 |
Why?
| | Systems Integration | 1 | 2016 | 36 | 0.030 |
Why?
| | Aged, 80 and over | 3 | 2013 | 8430 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2016 | 83 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 813 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 163 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2016 | 168 | 0.030 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 97 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2016 | 325 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2016 | 298 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3660 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 948 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2020 | 886 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2013 | 79 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 615 | 0.020 |
Why?
| | Acute Disease | 1 | 2016 | 1049 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3448 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 498 | 0.020 |
Why?
| | Sp3 Transcription Factor | 1 | 2011 | 6 | 0.020 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 26 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 374 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2011 | 88 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2011 | 139 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 855 | 0.020 |
Why?
| | Middle Aged | 4 | 2016 | 36821 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 337 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2011 | 512 | 0.020 |
Why?
| | Bronchi | 1 | 2011 | 263 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 509 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 1457 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1186 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1730 | 0.020 |
Why?
| | Alleles | 1 | 2011 | 909 | 0.020 |
Why?
| | Aged | 3 | 2013 | 26514 | 0.020 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 648 | 0.020 |
Why?
| | Child | 2 | 2020 | 22979 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6543 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1253 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 7274 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1875 | 0.020 |
Why?
| | Female | 4 | 2020 | 80076 | 0.020 |
Why?
| | Adult | 3 | 2016 | 41405 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2013 | 928 | 0.010 |
Why?
| | Fibroblasts | 1 | 2011 | 1039 | 0.010 |
Why?
| | Smoking | 1 | 2011 | 1483 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1195 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4169 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 4383 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 6099 | 0.010 |
Why?
| | Male | 3 | 2013 | 73950 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 14437 | 0.010 |
Why?
| | Mice | 1 | 2016 | 18491 | 0.010 |
Why?
| | Lung | 1 | 2011 | 4141 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 22825 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2013 | 17560 | 0.010 |
Why?
| | Animals | 1 | 2016 | 38410 | 0.010 |
Why?
|
|
Donahue's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|